Navigation Links
NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology

SOPHIA ANTIPOLIS, France, Oct. 2 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced the presentation of promising clinical and preclinical results from its collaboration with Ferrer Grupo International at the 21st World Congress of Dermatology, in Buenos Aires, Argentina. These included phase 1 results for NCX 1022, a prototype compound, showing the potential for improved safety and tolerability and preclinical results for a novel, high potency, nitric oxide-donating anti-inflammatory suggesting it could have enhanced anti-inflammatory activity over current dermatology products.

Ennio Ongini, Vice President of Research at NicOx, declared: "We are delighted to present these very promising results with Ferrer at this prestigious scientific meeting. These results highlight the potential of our technology in dermatology and suggest our joint program with Ferrer has the potential to provide more effective drugs to treat chronic skin disorders, which represent an increasing burden on medical services. Furthermore, the clinical data on NCX 1022 suggest that nitric oxide donation may also improve the safety margin over current treatments. We will continue to work closely with Ferrer to bring our promising drug candidate into clinical trials."

NicOx and Ferrer initiated their development program focused on high potency, nitric oxide-donating anti-inflammatory agents, for the treatment of a range of skin disorders (see NOTE), following encouraging results from a phase 1 study for NCX 1022, a lower potency prototype (see top-line results in press release of April 29, 2004). This presentation at the World Congress of Dermatology was the first time these results were presented at a scientific meeting. The results showed that the application of NCX 1022 ointment did not induce skin blanching with there being statistically significantly less skin blanching with NCX 1022 compared with three commonly used marketed products (p<0.001).

In parallel, NicOx and Ferrer jointly presented a series of preclinical results from a novel, high potency, nitric oxide-donating anti-inflammatory compound at the congress, which showed a broader anti-inflammatory activity than commonly used treatments for skin disorders. These results were obtained in a validated preclinical model of skin disorders by following selected biological markers involved in inflammatory pathways (namely pro-inflammatory mediators such as PGE2, cytokines and TNF-alpha). Scientists have proposed a role for nitric oxide in a number of biological processes in the skin.

Antonio Guglietta, Head of Research and Development at Ferrer, commented: "Nitric oxide is thought to play an important role in the physiology of the skin and these new preclinical results suggest nitric oxide-donating anti- inflammatory agents could have improved efficacy over existing treatments. We believe this collaboration with NicOx can lead to the successful development of a more effective and safer treatment for skin disorders."

NOTE: NicOx and Ferrer aim to develop an improved product to treat a range of skin disorders, including Atopic Dermatitis, Psoriasis and Seborrheic Dermatitis, which affect millions of people each year. The severity of these

conditions can vary widely and in the worst cases they can be painful, increase the risk of infection and cause social isolation due to appearance.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck & Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risk factors described in the company's document de reference.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/12/2015)... Ga. , Oct. 12, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and ... revenue results for the third quarter of 2015, its ... the Company has secured a $50 million Senior Secured ...
(Date:10/12/2015)... -- This study focuses on China,s ... past decades, the industry has been growing at a fast ... consumer consumptions in China have transformed ... China is one of the world,s major producers ... the world, China is the world,s ...
(Date:10/12/2015)... SACRAMENTO, Calif. , Oct. 12, 2015  In ... month in the Journal of Neurology, Neurosurgery, and Psychiatry, ... to reduce brain atrophy and cognitive decline in patients ... --> --> IVIG, extracted ... contains antibodies to amyloid, an abnormal brain protein found ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... An increasing number of Florida’s ... has partnered with the Florida Department of Health and its Bureau of Tobacco ... Smoke-Free Multifamily Housing Program launched last week at the organization’s 2015 Annual Conference ...
(Date:10/13/2015)... ... October 13, 2015 , ... ActivePDF, ... new PDF automation tool to batch conversions of CAD drawings, plans, and ... document fidelity. , CADConverter eliminates the complexity requirement of specialized applications to view ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... solutions for drugs, biologics, consumer health and animal health products, today announced that ... lead a new, dedicated global team of drug development and technology experts. , ...
(Date:10/12/2015)... , ... October 13, 2015 , ... North American Tool ... at the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... quality, and standards of excellence that customers have come to expect from members of ...
(Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in ... and skin care equipment, will be displaying custom sauna and steam room solutions at ... high-end resorts and spas as customers, SpaEquip is recognized for their ability to assist ...
Breaking Medicine News(10 mins):